psychopharmacology

This week we talk about drugs and how genetics might play a part in how they affect different people. Doug , as part of an IMPACT study in pharmacogenetics, discovers he metabolizes slowly, so medicinal treatments need to be adjusted accordingly. We also discuss his battles with the Ministry of Health and drugs not covered by the Ontario Health Insurance Plan (OHIP).

Ed takes the Hamilton Depression Scale test (HAM-D) to measure his depression level. How does the supposedly “normal” half of the Unhinged team rate? Doug also covers helpful tools for depressive disorder, including diet, positive self-talk, journaling, and more.

And finally, we get a progress report on Doug’s current state. What did he score on the HAM-D test?

Podcast: Play in new window | Download (Duration: 51:25 — 69.0MB)

Show resources:

Dr. Roger S. McIntyre

Monday June 6th, 2016 -Met with Dr. McIntyre today for my 2nd consult with him. Now that the DBS is working to some degree, will Dr. McIntyre have some insight into whether or not supplementation on the biochemical side will possibly help the DBS in it’s work? And what does his latest research suggest, given my mood, fluctuation patters, and from a full-scale picture, in the way of medications that are NOT typically used for TRD.

*More in tomorrow’s post; and you won’t believe what he said…

Dr. Roger S. McIntyre MD, FRCPC
Head, Mood Disorders Psychopharmacology Unit (UHN)

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and the Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada.

He was named by Thomson Reuters in 2014 as one of “The World’s Most Influential Scientific Minds”. This distinction is bestowed upon researchers who publish the most highly cited articles in a variety of scientific fields during the previous decade.

He is also extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto’s Department of Psychiatry and has been selected for the joint Canadian Psychiatric Association (CPA)/Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre is the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders. He has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders.

He completed his medical degree at Dalhousie University and completed his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.

Research Interests

Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity. Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.

Links:

Dr.McIntyre’s UHN Profile

Dr.McIntyre’s Research Publications

Dr. Roger McIntyre: Mood Disorders and Metabolic-Inflammatory Comorbidity -YouTube Video

Toronto Western Hospital (UHN)

Unhinged Episode #012: Psychopharmacology and Pharmacogenetics

Show resources:

Doug’s 2nd Consultation with Dr. Roger S. McIntyre